1
|
Xiong SQ, Chen Y, Wang LJ, Lyu PP, Liao W, Wang C, Ke JL, Zhu X, Wang JY, Shen XY, Li GP, Lin LZ. Usage of Chinese Herbs in Cancer Patients in Southern China: A Survey. Chin J Integr Med 2020; 27:502-508. [PMID: 32388824 DOI: 10.1007/s11655-019-3184-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/28/2019] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To study the use of Chinese medicine (CM) in cancer patients in southern China. METHODS A total of 1,950 cancer patients finished questionnaires in four provinces in southern China. The survey included socio-demographic and clinical characteristics of participants, dosage forms, efficacy, and side effects. RESULTS The study results showed that cancer patients with higher education (>12 years) were more likely to accept the treatment of Chinese herbs. There were 54.61% (1,065 cases) of patients chose Chinese herbs for the initial treatment and 14.46% (282 cases) chose Chinese herbs as monotherapy. Most patients (54.51%, 1,063 cases) continuously used CM for more than 6 months, and a few of them (212 cases) used CM for up to 3 years. All kinds of dosage forms of CM had been used, including CM decoction, CM patent prescription and CM injection. Concerning the efficacy in the view of patients, 40.31% (786 cases) believed that it would be effective to take Chinese herbs before they starting the anti-cancer treatment, and the percentage increased to 81.08% after 1-month CM treatment. The effect of Chinese herbs was mainly demonstrated by symptom relief and improvement of quality of life, and 8.31% (162 cases) of patients experienced control of tumor growth and decreased tumor markers. Furthermore, only 14.31% (279 cases) participants reported that they experienced side effects during CM treatment. CONCLUSION This large scale investigation reflects the current situation of domestic CM usage objectively and comprehensively, which might provide new ways for cancer treatment.
Collapse
Affiliation(s)
- Shao-Quan Xiong
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Yu Chen
- Department of Oncology, Friendship Hospital of Sichuan Provincial People's Hospital, Sichuan Province, Chengdu, 610000, China
| | - Li-Juan Wang
- Department of Oncology, Traditional Chinese Medicine Hospital of Shaanxi Province, Shaanxi Province, Xi'an, 710000, China.,School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610075, China
| | - Pan-Pan Lyu
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Wan Liao
- State Key Laboratory of Characteristic Chinese Drug Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
| | - Cui Wang
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Jian-Long Ke
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Xi Zhu
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Jin-Yang Wang
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Xian-Ying Shen
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Guang-Ping Li
- Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China
| | - Li-Zhu Lin
- Department of Oncology, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510405, China.
| |
Collapse
|